1.Research progress on the role of heat shock protein 27 in prostate cancer
Xian CHEN ; Wenjing GUO ; Liliang YANG ; Yuxin ZHOU ; Qinglong GUO
Journal of China Pharmaceutical University 2020;51(6):731-738
Prostate cancer is one of the most common cancers in adult men. Heat shock proteins (HSPs),as molecular chaperones widely involved in the pathogenesis,diagnosis,treatment and prognosis of various cancers,play crucial biological functions in prostate cancer and it can be considered as valuable biomarkers for cancer therapy, such as prostate-specific membrane antigen. As a member of the heat shock protein family, HSP27 is related to prostate cancer castration resistance,and its expression can promote tumor resistance,invasion and bone metastasis,making prostate cancer more invulnerable to treatments. Therefore,targeting HSP27 in prostate cancer can be perceived as one promising cancer treatment strategy. This article reviews the structure and function of HSP27,and its potential role on castration resistance and targeted therapy in order to provide a new theoretical basis for the clinical treatment of prostate cancer.
2.Investigation of coordinated development between blood banks and apheresis plasma collection banks
Qun LIU ; Dunzhu GONGJUE ; Qian ZHANG ; Hui YE ; Hua SHEN ; Mingming QIAO ; Linwei LI ; Xingzhe ZHANG ; Xiangwen CHEN ; Liliang CHEN ; Yang LIU ; Yunlong ZHUANG
Chinese Journal of Blood Transfusion 2024;37(8):927-932
Objective To explore the factors that affect the coordinated development of blood banks and apheresis plas-ma collection banks(hereinafter referred to as plasma banks),and explore feasible measures for the coordinated develop-ment of blood banks and plasma banks.Methods The blood information management system and blood source information management system were used to retrieve related data of blood and plasma donation from 9 cities in Shandong province from 2017 to 2021.The number of blood donors and plasma donors and the intersection of them were analyzed.The data analysis was performed using chi-square test,and a questionnaire survey was conducted to investigate the policies and information status,as well as expectations for coordinated development for blood and plasma donation.Results From 2017 to 2021,the total number of blood donors in 9 cities was higher than that of plasma donors,both have been increasing year by year,and the increase in plasma donors was significantly higher than that of blood donors(131.78%vs 23.90%,P<0.05).The inter-section proportion of blood and plasma donors had increased from 0.45%in 2017 to 1.04%in 2021,with an increase of 131.11%.Among the administrative regions where the participating blood and plasma banks located,94.2%have not re-leased relevant policy to promote the coordinated development of blood and plasma donation.The majority(63%)expected blood banks and plasma banks to be set at a distance more than 50 km apart.The top four functional requirements for the in-terconnection between blood banks and plasma banks management information system were blood test results(94.61%),ID number(87.54%),blood and plasma donation records(85.51%)and health consultation/examination results(82.15%).The top four elements of coordinated development between blood and plasma banks were policy support(96.25%),informa-tion networking(92.36%),top-level design(87.44%)and cultural construction(86.58%).Conclusion The number of donors who donate both blood(mainly whole blood)and plasma has been increasing year by year,which deserves our close attention.To achieve the coordinated development of blood donation and plasma donation,policy support is the most crucial and fundamental means.Establishment of a standard system and the share of blood and plasma donation information is neces-sary for blood informatization construction.It was critical to promote the coordinated development of blood and plasma dona-tion and ensure blood safety with improving legislation,formulating policies for coordinated development,strengthening top-level design,standardizing the publicity of blood and plasma donation and establishing the idea that blood and plasma dona-tion are equally honorable.
3.Efficacy and Safety of Rivaroxaban versus Low Molecular Weight Heparin in the Prevention of Venous Thromboembolism in Patients with Hip Fracture :A Meta-analysis
Liliang WANG ; Jin JIN ; Yang YANG ; Zhengxiang LI ; Hengjie YUAN
China Pharmacy 2019;30(1):120-124
OBJECTIVE: To systematically evaluate the efficacy and safety of rivaroxaban versus low molecular weight heparin in the prevention of venous thromboembolism (VTE) in patients with hip fractures, and to provide evidence-based reference for clinical application. METHODS: Retrieved from Cochrane library, PubMed, Embase, CNKI, VIP and Wanfang database, randomized controlled trials (RCTs) about rivaroxaban (test group) versus low molecular weight heparin (control group) in the prevention of VTE in patients with hip fracture were collected during database establishment to Jun. 2018. After data extraction and quality evaluation with Cochrane system evaluator manual 5.1.0, Meta-analysis was performed by using Rev Man 5.3 statistical software for the incidence of deep venous thrombosis (DVT), postoperative discharge, activated partial thromboplastin time (APTT), prothrombin time (PT) and the incidence of ADR. RESULTS: Totally 8 RCTs were included, involving 949 patients. Results of Meta-analysis showed that compared with low molecular weight heparin, rivaroxaban could significantly decreased the incidence of DVT [RR=0.55, 95%CI (0.36, 0.83), P=0.004]. There was no statistical significance in postoperative discharge [MD=-0.24, 95%CI (-5.27, 4.8), P=0.93], APTT [MD=0.56, 95%CI (-0.75, 1.86), P=0.40], PT [MD=0.04, 95%CI(-0.03, 0.11), P=0.25] or the incidence of ADR [RR=1.73,95%CI(0.15,20.48), P=0.66] between 2 groups. CONCLUSIONS: Rivaroxaban has a better preventive effect on VTE in patients with hip fracture than low molecular weight heparin, and has a similar safety as low molecular weight heparin.